ArticleFuture oncology (London, England)2026

Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice.

Stephen J Freedland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.